Replies to post #242495 on Biotech Values

[DewDiligence]

AZN told investors, “There is no clear path for Roxa approval in the US.”

[DewDiligence]

AKBA receives $55M cash from Otsuka for termination of Vadadustat partnership in all geographies:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001517022/000119312522186174/d323865d8k.htm

As the Company previously announced on a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 13, 2022, Otsuka gave the Company notice of termination of the Collaboration Agreements. Under the terms of the Termination Agreement, Otsuka will (i) pay the Company a nonrefundable and non-creditable payment of $55,000,000 in consideration for the covenants and agreements set forth in the Termination Agreement...